IC-351 -: Treatment of erectile dysfunction -: Treatment of female sexual dysfunction -: Phosphodiesterase 5 inhibitor

被引：45

作者：

Sorbera, LA ^{[1
]}

Martín, L ^{[1
]}

Leeson, PA ^{[1
]}

Castañer, J ^{[1
]}

机构：

[1] Pros Sci, Barcelona 08080, Spain

来源：

关键词：

(6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-1,2,3,4,6,7,12,12a-octahydropyrazino[2 ',1 ': 6,1]pyrido[3,4-b]indole-1,4-dione;

D O I：

10.1358/dof.2001.026.01.606182

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：15 / 19

页数：5

共 19 条

[1]

ALLEMEIER LL, Patent No. 0066114

[2]

ANGLIN G, 2000, INT J IMPOT RES S3, V12

[3]

BENET AE, 1995, UROL CLIN N AM, V22, P699

[4] Cyclic GMP phosphodiesterase-5: Target of sildenafil [J].

Corbin, JD ;

Francis, SH .

[5]

Daugan A. C. M., U. S. Patent, Patent No. [5, 859, 006, 5859006]

[6]

DAUGAN AC, Patent No. 9519978

[7]

DAUGAN ACM, Patent No. 6025494

[8]

DAUGAN ACM, Patent No. 1997508113

[9]

DAUGAN ACM, Patent No. 199509221

[10]

DAUGAN ACM, Patent No. 0740668